Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Share-based Compensation (2016 - 2025)

Voyager Therapeutics' Share-based Compensation history spans 11 years, with the latest figure at $3.5 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 5.78% year-over-year to $3.5 million; the TTM value through Dec 2025 reached $14.8 million, changed 0.01%, while the annual FY2025 figure was $14.8 million, 0.01% changed from the prior year.
  • Share-based Compensation for Q4 2025 was $3.5 million at Voyager Therapeutics, up from $3.5 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $4.1 million in Q2 2025 and bottomed at $1.7 million in Q4 2021.
  • The 5-year median for Share-based Compensation is $3.2 million (2023), against an average of $3.1 million.
  • The largest annual shift saw Share-based Compensation crashed 52.77% in 2021 before it surged 51.27% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $1.7 million in 2021, then skyrocketed by 41.84% to $2.3 million in 2022, then grew by 29.8% to $3.0 million in 2023, then grew by 22.73% to $3.7 million in 2024, then fell by 5.78% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Share-based Compensation are $3.5 million (Q4 2025), $3.5 million (Q3 2025), and $4.1 million (Q2 2025).